Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2022. | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2021.
|
or
☐
| ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________. |
Commission File Number: 333-82900 
ThermoGenesis Holdings, Inc. (Exact name of registrant as specified in its charter) |
| | | |
Delaware (State of incorporation) | | 94-3018487 (I.R.S. Employer Identification No.) |
| | | |
2711 Citrus Road Rancho Cordova, California 95742 (Address of principal executive offices) (Zip Code) |
|
(916) 858-5100 (Registrant’s telephone number, including area code) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading symbol(s) | | Name of each exchange on which registered |
Common Stock, $.001 par value | | THMO | | Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class | | Outstanding at August 11, 2021May 18, 2022 |
Common stock, $.001 par value | | 11,911,78412,829,877
|
ThermoGenesis Holdings, Inc.
INDEX
Page Number
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ThermoGenesis Holdings, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| | | June 30, 2021 | | | December 31, 2020 | | | March 31, 2022 | | | December 31, 2021 | |
ASSETS | | | | | |
Current assets: | | |
Cash and cash equivalents | | $ | 8,668,000 | | | $ | 7,161,000 | | | $ | 3,652,000 | | | $ | 7,280,000 | |
Accounts receivable, net of allowance for doubtful accounts of $214,000 at June 30, 2021 and December 31, 2020 | | 1,242,000 | | | 1,382,000 | | |
Accounts receivable, net of allowance for doubtful accounts of $156,000 at March 31, 2022 and December 31, 2021 | | | 2,175,000 | | | 733,000 | |
Inventories | | 5,813,000 | | | 5,877,000 | | | 5,893,000 | | | 5,373,000 | |
Prepaid expenses and other current assets | | | 354,000 | | | | 878,000 | | | | 1,474,000 | | | | 1,578,000 | |
Total current assets | | 16,077,000 | | | 15,298,000 | | | 13,194,000 | | | 14,964,000 | |
| | | |
Inventories, non-current | | 2,227,000 | | | 1,221,000 | | |
Inventories non-current, net | | | 1,197,000 | | | 1,709,000 | |
Equipment and leasehold improvements, net | | 1,282,000 | | | 1,424,000 | | | 1,224,000 | | | 1,261,000 | |
Right-of-use operating lease assets, net | | 654,000 | | | 730,000 | | | 525,000 | | | 571,000 | |
Goodwill | | 781,000 | | | 781,000 | | | 781,000 | | | 781,000 | |
Other intangible assets, net | | 1,334,000 | | | 1,358,000 | | | 1,310,000 | | | 1,318,000 | |
Other assets | | | 48,000 | | | | 48,000 | | | | 48,000 | | | | 48,000 | |
Total assets | | $ | 22,403,000 | | | $ | 20,860,000 | | | $ | 18,279,000 | | | $ | 20,652,000 | |
| | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | |
LIABILITIES AND EQUITY | | |
Current liabilities: | | |
Accounts payable | | $ | 1,120,000 | | | $ | 1,366,000 | | | $ | 1,866,000 | | | $ | 1,280,000 | |
Accrued payroll and related expenses | | 345,000 | | | 349,000 | | | 456,000 | | | 348,000 | |
Deferred revenue – short-term | | 903,000 | | | 608,000 | | | 1,159,000 | | | 719,000 | |
Convertible promissory note – related party, net | | 7,590,000 | | | -- | | |
Convertible promissory note – related party | | | 10,000,000 | | | -- | |
Interest payable – related party | | 1,106,000 | | | 2,082,000 | | | 153,000 | | | 2,231,000 | |
Note payable – short-term | | -- | | | 447,000 | | |
Convertible promissory note, net | | | 1,000,000 | | | 813,000 | |
Other current liabilities | | | 847,000 | | | | 1,291,000 | | | | 843,000 | | | | 957,000 | |
Total current liabilities | | 11,911,000 | | | 6,143,000 | | | 15,477,000 | | | 6,348,000 | |
| | | |
Convertible promissory note – related party, net | | -- | | | 5,935,000 | | | -- | | | 9,245,000 | |
Convertible promissory notes, net | | 653,000 | | | 493,000 | | |
Note payable | | -- | | | 199,000 | | |
Operating lease obligations – long-term | | 508,000 | | | 604,000 | | | 338,000 | | | 398,000 | |
Deferred revenue – long-term | | 1,442,000 | | | 1,596,000 | | | 1,163,000 | | | 1,244,000 | |
Other noncurrent liabilities | | | 20,000 | | | | 20,000 | | | | 19,000 | | | | 20,000 | |
Total liabilities | | | 14,534,000 | | | | 14,990,000 | | | | 16,997,000 | | | | 17,255,000 | |
| | | |
Commitments and contingencies | | | | | | | | | |
| | | |
Stockholders’ equity: | | |
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding | | -- | | | -- | | | -- | | | -- | |
Common stock, $0.001 par value; 350,000,000 shares authorized; 11,911,784 issued and outstanding (8,934,952 at December 31, 2020) | | 12,000 | | | 9,000 | | |
| | | |
Common stock, $0.001 par value; 350,000,000 shares authorized; 12,829,877 issued and outstanding (11,911,784 at December 31, 2021) | | | 13,000 | | | 12,000 | |
Additional paid in capital | | 268,244,000 | | | 259,058,000 | | | 258,614,000 | | | 268,447,000 | |
Accumulated deficit | | (260,235,000 | ) | | (253,283,000 | ) | | (256,833,000 | ) | | (264,662,000 | ) |
Accumulated other comprehensive loss | | | 29,000 | | | | 16,000 | | | | 45,000 | | | | 31,000 | |
Total ThermoGenesis Holdings, Inc. stockholders’ equity | | 8,050,000 | | | 5,800,000 | | | 1,839,000 | | | 3,828,000 | |
| | | |
Noncontrolling interests | | | (181,000 | ) | | | 70,000 | | | | (557,000 | ) | | | (431,000 | ) |
Total equity | | | 7,869,000 | | | | 5,870,000 | | | | 1,282,000 | | | | 3,397,000 | |
Total liabilities and equity | | $ | 22,403,000 | | | $ | 20,860,000 | | | $ | 18,279,000 | | | $ | 20,652,000 | |
See accompanying notes.notes to the condensed consolidated financial statements.
ThermoGenesis Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| | | Three Months Ended
June 30, | | Six Months Ended June 30, | | | Three Months Ended
March 31, | |
| | | 2021 | | | 2020 | | | 2021 | | | 2020 | | | 2022 | | | 2021 | |
| | | |
Net revenues | | $ | 2,201,000 | | | $ | 2,242,000 | | | $ | 3,718,000 | | | $ | 5,442,000 | | | $ | 2,663,000 | | | $ | 1,517,000 | |
Cost of revenues | | | 1,215,000 | | | | 4,874,000 | | | | 2,024,000 | | | | 6,582,000 | | | | 1,723,000 | | | | 809,000 | |
| | | |
Gross profit (loss) | | | 986,000 | | | | (2,632,000 | ) | | | 1,694,000 | | | | (1,140,000 | ) | |
Gross profit | | | | 940,000 | | | | 708,000 | |
| | | |
Expenses: | | |
| | | |
Selling, general and administrative | | 3,502,000 | | | 1,978,000 | | | 5,494,000 | | | 4,070,000 | | | 1,693,000 | | | 1,992,000 | |
Research and development | | | 622,000 | | | | 578,000 | | | | 1,001,000 | | | | 1,187,000 | | | | 456,000 | | | | 379,000 | |
| | | |
Total operating expenses | | | 4,124,000 | | | | 2,556,000 | | | | 6,495,000 | | | | 5,257,000 | | | | 2,149,000 | | | | 2,371,000 | |
| | | |
Loss from operations | | (3,138,000 | ) | | (5,188,000 | ) | | (4,801,000 | ) | | (6,397,000 | ) | | (1,209,000 | ) | | (1,663,000 | ) |
| | | |
Other expenses: | | |
| | | |
Other income (expenses): | | |
Interest expense | | (1,524,000 | ) | | (1,314,000 | ) | | (3,043,000 | ) | | (4,845,000 | ) | | (823,000 | ) | | (1,519,000 | ) |
Other income (expenses) | | (10,000 | ) | | (8,000 | ) | | (11,000 | ) | | (11,000 | ) | | (4,000 | ) | | (1,000 | ) |
Gain on extinguishment of debt | | | -- | | | | -- | | | | 652,000 | | | | -- | | |
Total other expense | | | (1,534,000 | ) | | | (1,322,000 | ) | | | (2,402,000 | ) | | | (4,856,000 | ) | |
| | | |
Gain / (loss) on extinguishment of debt | | | | -- | | | | 652,000 | |
Total other expenses | | | | (827,000 | ) | | | (868,000 | ) |
| | | |
Net loss | | | (4,672,000 | ) | | | (6,510,000 | ) | | | (7,203,000 | ) | | | (11,253,000 | ) | | | (2,036,000 | ) | | | (2,531,000 | ) |
| | | |
Loss attributable to noncontrolling interests | | | (133,000 | ) | | | (73,000 | ) | | | (251,000 | ) | | | (214,000 | ) | | | (126,000 | ) | | | (118,000 | ) |
Net loss attributable to common stockholders | | $ | (4,539,000 | ) | | $ | (6,437,000 | ) | | $ | (6,952,000 | ) | | $ | (11,039,000 | ) | | $ | (1,910,000 | ) | | $ | (2,413,000 | ) |
| | | |
COMPREHENSIVE LOSS | | |
Net loss | | $ | (4,672,000 | ) | | $ | (6,510,000 | ) | | $ | (7,203,000 | ) | | $ | (11,253,000 | ) | | $ | (2,036,000 | ) | | $ | (2,531,000 | ) |
Other comprehensive loss: | | |
Foreign currency translation adjustments gain (loss) | | | 12,000 | | | | 1,000 | | | | 13,000 | | | | 39,000 | | | | 14,000 | | | | 1,000 | |
Comprehensive loss | | (4,660,000 | ) | | (6,509,000 | ) | | (7,190,000 | ) | | (11,214,000 | ) | | (2,022,000 | ) | | (2,530,000 | ) |
Comprehensive loss attributable to noncontrolling interests | | | (133,000 | ) | | | (73,000 | ) | | | (251,000 | ) | | | (214,000 | ) | | | (126,000 | ) | | | (118,000 | ) |
Comprehensive loss attributable to common stockholders | | $ | (4,527,000 | ) | | $ | (6,436,000 | ) | | $ | (6,939,000 | ) | | $ | (11,000,000 | ) | | $ | (1,896,000 | ) | | $ | (2,412,000 | ) |
| | | |
Per share data: | | |
| | | |
Basic and diluted net loss per common share | | $ | (0.38 | ) | | $ | (1.02 | ) | | $ | (0.59 | ) | | $ | (2.11 | ) | | $ | (0.16 | ) | | $ | (0.21 | ) |
| | | |
Weighted average common shares outstanding – basic and diluted | | | 11,911,784 | | | | 6,315,566 | | | | 11,679,075 | | | | 5,230,921 | | |
Weighted average common shares outstanding basic and diluted | | | | 12,288,517 | | | | 11,446,366 | |
See accompanying notes.notes to the condensed consolidated financial statements.
ThermoGenesis Holdings, Inc.
Condensed Consolidated Statements of Equity
For the Three and Six Months Ended June 30,March 31, 2022 and 2021 and 2020
(Unaudited)
| | | Shares | | | Common Stock | | | Paid in Capital in Excess of Par | | | Accumulated Deficit | | | AOCL* | | | Non- Controlling interests | | | Total Equity | |
Balance at January 1, 2021 | | | 8,934,952 | | | $ | 9,000 | | | $ | 259,058,000 | | | $ | (253,283,000 | ) | | $ | 16,000 | | | $ | 70,000 | | | $ | 5,870,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Stock-based compensation expense | | | -- | | | | -- | | | | 258,000 | | | | -- | | | | -- | | | | -- | | | | 258,000 | |
Issuance of common stock via at-the-market offering, net | | | 2,976,832 | | | | 3,000 | | | | 6,829,000 | | | | -- | | | | -- | | | | -- | | | | 6,832,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 1,000 | | | | -- | | | | 1,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (2,413,000 | ) | | | -- | | | | (118,000 | ) | | | (2,531,000 | ) |
Balance at March 31, 2021 | | | 11,911,784 | | | $ | 12,000 | | | $ | 266,145,000 | | | $ | (255,696,000 | ) | | $ | 17,000 | | | $ | (48,000 | ) | | $ | 10,430,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Stock-based compensation expense | | | -- | | | | -- | | | | 2,099,000 | | | | -- | | | | -- | | | | -- | | | | 2,099,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 12,000 | | | | -- | | | | 12,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (4,539,000 | ) | | | -- | | | | (133,000 | ) | | | (4,672,000 | ) |
Balance at June 30, 2021 | | | 11,911,784 | | | $ | 12,000 | | | $ | 268,244,000 | | | $ | (260,235,000 | ) | | $ | 29,000 | | | $ | (181,000 | ) | | $ | 7,869,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance at January 1, 2020 | | | 2,843,601 | | | $ | 3,000 | | | $ | 237,313,000 | | | $ | (236,932,000 | ) | | $ | 2,000 | | | $ | 530,000 | | | $ | 916,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Stock-based compensation expense | | | -- | | | | -- | | | | 67,000 | | | | -- | | | | -- | | | | -- | | | | 67,000 | |
Exercise of pre-funded warrants | | | 100,000 | | | | -- | | | | 10,000 | | | | -- | | | | -- | | | | -- | | | | 10,000 | |
Exercise of warrants | | | 7,866 | | | | -- | | | | 47,000 | | | | -- | | | | -- | | | | -- | | | | 47,000 | |
Discount due to beneficial conversion features | | | -- | | | | -- | | | | 1,869,000 | | | | -- | | | | -- | | | | -- | | | | 1,869,000 | |
Conversion of related party note payable to common stock | | | 1,666,670 | | | | 2,000 | | | | 2,998,000 | | | | -- | | | | -- | | | | -- | | | | 3,000,000 | |
Conversion of note payable to common stock | | | 100,000 | | | | -- | | | | 180,000 | | | | -- | | | | -- | | | | -- | | | | 180,000 | |
Issuance of common stock, net | | | 1,050,748 | | | | 1,000 | | | | 3,220,000 | | | | -- | | | | -- | | | | -- | | | | 3,221,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 38,000 | | | | -- | | | | 38,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (4,602,000 | ) | | | -- | | | | (141,000 | ) | | | (4,743,000 | ) |
Balance at March 31, 2020 | | | 5,768,885 | | | $ | 6,000 | | | $ | 245,704,000 | | | $ | (241,534,000 | ) | | $ | 40,000 | | | $ | 389,000 | | | $ | 4,605,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Stock-based compensation expense | | | -- | | | | -- | | | | 314,000 | | | | -- | | | | -- | | | | -- | | | | 314,000 | |
Exercise of pre-funded warrants | | | 224,445 | | | | | | | | 22,000 | | | | -- | | | | -- | | | | -- | | | | 22,000 | |
Exercise of warrants | | | 267,271 | | | | -- | | | | 1,604,000 | | | | -- | | | | -- | | | | -- | | | | 1,604,000 | |
Discount due to beneficial conversion features | | | -- | | | | -- | | | | 3,112,000 | | | | -- | | | | -- | | | | -- | | | | 3,112,000 | |
Conversion of note payable to common stock | | | 104,445 | | | | 1,000 | | | | 188,000 | | | | -- | | | | -- | | | | -- | | | | 189,000 | |
Issuance of Common Stock, net | | | 344,419 | | | | -- | | | | 1,993,000 | | | | -- | | | | -- | | | | -- | | | | 1,993,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 1,000 | | | | -- | | | | 1,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (6,437,000 | ) | | | | | | | (73,000 | ) | | | (6,510,000 | ) |
Balance at June 30, 2020 | | | 6,709,465 | | | $ | 7,000 | | | $ | 252,937,000 | | | $ | (247,971,000 | ) | | $ | 41,000 | | | $ | 316,000 | | | $ | 5,330,000 | |
| | | Shares | | | Common Stock | | | Paid in Capital in Excess of Par | | | Accumulated Deficit | | | AOCL* | | | Non- Controlling interests | | | Total Equity | |
Balance at January 1, 2022 | | | 11,911,784 | | | $ | 12,000 | | | $ | 268,447,000 | | | $ | (264,662,000 | ) | | $ | 31,000 | | | $ | (431,000 | ) | | $ | 3,397,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adoption of ASU 2020-06 | | | -- | | | | -- | | | | (10,681,000 | ) | | | 9,739,000 | | | | -- | | | | -- | | | | (942,000 | ) |
Stock-based compensation expense | | | -- | | | | -- | | | | 42,000 | | | | -- | | | | -- | | | | -- | | | | 42,000 | |
Issuance of common stock via at-the-market offering, net | | | 918,093 | | | | 1,000 | | | | 593,000 | | | | -- | | | | -- | | | | -- | | | | 594,000 | |
Related party convertible note price reset | | | | | | | | | | | 213,000 | | | | | | | | | | | | | | | | 213,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 14,000 | | | | -- | | | | 14,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (1,910,000 | ) | | | -- | | | | (126,000 | ) | | | (2,036,000 | ) |
Balance at March 31, 2022 | | | 12,829,877 | | | $ | 13,000 | | | $ | 258,614,000 | | | $ | (256,833,000 | ) | | $ | 45,000 | | | $ | (557,000 | ) | | $ | 1,282,000 | |
| | | Shares | | | Common Stock | | | Paid in Capital in Excess of Par | | | Accumulated Deficit | | | AOCL* | | | Non-Controlling interests | | | Total Equity | |
Balance at January 1, 2021 | | | 8,934,952 | | | $ | 9,000 | | | $ | 259,058,000 | | | $ | (253,283,000 | ) | | $ | 16,000 | | | $ | 70,000 | | | $ | 5,870,000 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Stock-based compensation expense | | | -- | | | | -- | | | | 258,000 | | | | -- | | | | -- | | | | -- | | | | 258,000 | |
Issuance of common stock via at- the-market offering, net | | | 2,976,832 | | | | 3,000 | | | | 6,829,000 | | | | -- | | | | -- | | | | -- | | | | 6,832,000 | |
Foreign currency translation gain | | | -- | | | | -- | | | | -- | | | | -- | | | | 1,000 | | | | -- | | | | 1,000 | |
Net loss | | | -- | | | | -- | | | | -- | | | | (2,413,000 | ) | | | -- | | | | (118,000 | ) | | | (2,531,000 | ) |
Balance at March 31, 2021 | | | 11,911,784 | | | $ | 12,000 | | | $ | 266,145,000 | | | $ | (255,696,000 | ) | | $ | 17,000 | | | $ | (48,000 | ) | | $ | 10,430,000 | |
* Accumulated other comprehensive loss.
See accompanying notes.notes to the condensed consolidated financial statements.
ThermoGenesis Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| | | Six Months Ended June 30, | | | Three Months Ended March 31, | |
| | | 2021 | | | 2020 | | | 2022 | | | 2021 | |
Cash flows from operating activities: | | |
Net loss | | $ | (7,203,000 | ) | | $ | (11,253,000 | ) | | $ | (2,036,000 | ) | | $ | (2,531,000 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | | |
Depreciation and amortization | | 320,000 | | | 392,000 | | | 150,000 | | | 166,000 | |
Stock based compensation expense | | 2,357,000 | | | 381,000 | | |
Stock-based compensation expense | | | 42,000 | | | 258,000 | |
Amortization of debt discount/premium, net | | 1,815,000 | | | 1,257,000 | | | 213,000 | | | 908,000 | |
Amortization of accelerated debt discount due to conversion | | -- | | | 2,486,000 | | |
Reserve for excess and slow-moving inventories | | 98,000 | | | 3,744,000 | | | 374,000 | | | (4,000 | ) |
Loss on disposal of equipment | | -- | | | 114,000 | | |
Gain on extinguishment of debt | | (652,000 | ) | | -- | | | -- | | | (652,000 | ) |
Net change in operating assets and liabilities: | | |
Accounts receivable | | 140,000 | | | (378,000 | ) | | (1,442,000 | ) | | 556,000 | |
Inventories | | (1,042,000 | ) | | (5,108,000 | ) | | (383,000 | ) | | (718,000 | ) |
Prepaid expenses and other assets | | 524,000 | | | (65,000 | ) | | 103,000 | | | 148,000 | |
Accounts payable | | (236,000 | ) | | 1,812,000 | | | 599,000 | | | (38,000 | ) |
Interest payable - related party | | (976,000 | ) | | (912,000 | ) | |
Interest payable – related party | | | (2,078,000 | ) | | (1,532,000 | ) |
Accrued payroll and related expenses | | (4,000 | ) | | 238,000 | | | 107,000 | | | 124,000 | |
Deferred revenue – short-term | | 294,000 | | | 167,000 | | |
Deferred revenue – short term | | | 441,000 | | | 88,000 | |
Other current liabilities | | (434,000 | ) | | (1,607,000 | ) | | (112,000 | ) | | (603,000 | ) |
Long-term deferred revenue and other noncurrent liabilities | | | (245,000 | ) | | | (221,000 | ) | | | (137,000 | ) | | | (122,000 | ) |
| | | |
Net cash used in operating activities | | | (5,244,000 | ) | | | (8,953,000 | ) | | | (4,159,000 | ) | | | (3,952,000 | ) |
| | | |
Cash flows from investing activities: | | |
Capital expenditures | | | (80,000 | ) | | | (23,000 | ) | | | (65,000 | ) | | | (27,000 | ) |
| | | |
Net cash used in investing activities | | | (80,000 | ) | | | (23,000 | ) | | | (65,000 | ) | | | (27,000 | ) |
| | | |
Cash flows from financing activities: | | |
| | | |
Proceeds from convertible promissory note-related party | | -- | | | 4,287,000 | | |
Payments on financing lease obligations | | -- | | | (22,000 | ) | |
Proceeds from issuance of common stock, net of expenses | | 6,832,000 | | | 5,214,000 | | |
Proceeds from exercise of options, warrants and pre-funded warrants | | -- | | | 1,683,000 | | |
Proceeds from note payable | | | -- | | | | 646,000 | | |
| | | |
Proceeds from issuance of common stock, net of $87,000 in expenses | | | | 594,000 | | | | 6,832,000 | |
Net cash provided by financing activities | | | 6,832,000 | | | | 11,808,000 | | | | 594,000 | | | | 6,832,000 | |
| | | |
Effects of foreign currency rate changes on cash and cash equivalents | | | (1,000 | ) | | | (5,000 | ) | | | 2,000 | | | | -- | |
Net increase (decrease) in cash, cash equivalents and restricted cash | | 1,507,000 | | | 2,827,000 | | |
Net increase (decrease) in cash and cash equivalents | | | (3,628,000 | ) | | 2,853,000 | |
| | | |
Cash, cash equivalents and restricted cash at beginning of period | | | 7,161,000 | | | | 4,157,000 | | |
Cash, cash equivalents and restricted cash at end of period | | $ | 8,668,000 | | | $ | 6,984,000 | | |
Cash and cash equivalents at beginning of period | | | | 7,280,000 | | | | 7,161,000 | |
Cash and cash equivalents at end of period | | | $ | 3,652,000 | | | $ | 10,014,000 | |
| | | |
Supplemental disclosures of cash flow information: | | |
Cash paid for related party interest | | | $ | 2,628,000 | | | $ | 2,082,000 | |
Cash paid for interest | | $ | 2,202,000 | | | $ | 2,031,000 | | | $ | 60,000 | | | $ | 60,000 | |
Supplemental non-cash financing and investing information: | | |
Recording of beneficial conversion feature on debt | | $ | -- | | | $ | 4,981,000 | | |
Related party promissory note converted to common stock | | $ | -- | | | $ | 3,000,000 | | |
Convertible promissory note converted to common stock | | $ | -- | | | $ | 369,000 | | |
| Related party convertible note price reset | | | $ | 213,000 | | | | -- | |
See accompanying notes.notes to the condensed consolidated financial statements.
ThermoGenesis Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business
Description of Business
ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”),The Company develops commercializes and marketscommercializes a range of automated technologies for CAR-Tcell-banking, cell-processing, and other cell-based therapies. The Company currently marketstherapeutics. Since the 1990’s ThermoGenesis Holdings has been a full suitepioneer in, and a leading provider of solutions for automated clinical biobanking, point-of-care applications,systems that isolate, purify and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing processcryogenically store units of hematopoietic stem and progenitor cells for the emerging CAR-T immunotherapy market.cord blood banking industry. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA.
Medical Device Products for Automated Cell Processing
The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications.large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements.
2. Going Concern
At March 31, 2022, the Company had cash and cash equivalents of $3,652,000 and working capital of $(2,283,000). The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. The Company may need to raise additional capital to grow its subsidiaries currently manufacturebusiness, fund operating expenses and marketmake interest payments. The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the following products:Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report.
Clinical Bio-Banking Applications:The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.
| ●
3. Summary of Significant Accounting Polices | AXP®IIAutomated Cell Separation System – an automated, fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510(k) medical device.
|
| ●
| BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510(k) medical device.
|
Point-of-Care Applications:There have been no material changes in the Company’s significant accounting policies to those disclosed in the 2021 Annual Report.
| ●
| PXP®Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics, registered as a U.S. FDA 510(k) medical device.
|
| ●
| PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510(k) medical device.
|
| ●
| PXP-1000 System – an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination, registered as a U.S. FDA 510(k) medical device.
|
Large Scale Cell Processing and Biomanufacturing:
| ●
| X-Series® Products: X-Lab® for cell isolation, X-Wash® System for cell washing and reformulation, X-Mini® for high efficiency small scale cell purification, and X-BACS® System under development for large scale cell purification using our proprietary buoyancy-activated cell sorting (“BACS”) technology.
|
| ●
| CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest.
|
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance.
Operating results for the three-month period ended June 30, 2021March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.2022. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings, Inc.Holdings’ Annual Report on Form 10-K for the year ended December 31, 2020.2021.
Principles of Consolidation
The consolidated financial statements include the accounts of ThermoGenesis Holdings Inc. and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.
The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.
Recently Adopted Accounting Standards
On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2020-06 “Debt-Debt with Conversion and Other Options (“Subtopic 470-20”) and Derivatives and Hedging-Contracts in Entity’s Own Equity (“Subtopic 815-40”):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,”using the modified retrospective method. ASU 2020-06 provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. The Company recognized a cumulative effect of $9,739,000 of initially applying the ASU as an adjustment to the January 1, 2022 opening balance of accumulated deficit. Due to the recombination of the equity conversion component of our convertible debt outstanding, additional paid in capital and the debt discounts of the convertible promissory notes were reduced $10,681,000 and $942,000, respectively.
2.4. GOING CONCERNRelated Party Transactions
AtConvertible Promissory Note and Revolving Credit Agreement
In June 30,March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of the Boyalife Group (USA), Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). As of December 31, 2021, the Company had cashan outstanding principal balance on the Loan of $10,000,000. On March 4, 2022, the Company amended the Loan extending the Maturity Date by one year to March 6, 2023.
The Credit Agreement and cash equivalentsthe Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of $8,668,000 and working capitalinterest-only due on the last day of $4,166,000.each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has incurred historical losses from operations and expectsfive business days after the Lender demands payment to continue to incur operating lossespay the interest due before the Loan is considered in the near future. These recurring losses raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing of this report.default. The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company’s ability to fund its cash needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debtLoan can be prepaid in whole or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable topart by the Company if at all.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.time without penalty.
The following summarizes the Note:
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 3/6/2023 | | | 22 | % | | $ | 0.64 | | | $ | 10,000,000 | |
At December 31, 2021 | 3/6/2022 | | | 22 | % | | $ | 1.80 | | | $ | 9,245,000 | |
The Note includes a down round provision that lowers its conversion price if the Company sells shares of common stock at a lower price per share. In February 2022, the Company sold shares of common stock at a price lower than the conversion price of the Note, resulting in a down round triggering event lowering the conversion price of the Note to $0.64 per share. The Company determined that the triggering event created incremental value of $213,000 which was treated as a debt discount and amortized over the remaining term of the Note. A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option with the following inputs:
| | | Before | | | After | |
Conversion Price | | $ | 1.80 | | | $ | 0.64 | |
Term (in years) | | | 0.02 | | | | 0.02 | |
Volatility | | | 39.53 | % | | | 39.53 | % |
Dividend rate | | | 0 | % | | | 0 | % |
Risk free rate | | | 1.97 | % | | | 1.97 | % |
The Company amortized $213,000 and $827,000 of debt discount to interest expense for the three months ended March 31, 2022 and 2021, respectively. In addition to the amortization, the Company also recorded interest expense of $550,000 for each of the quarters ended March 31, 2022 and 2021. The interest payable balance as of March 31, 2022 and December 31, 2021 was $153,000 and $2,231,000, respectively.
On March 4, 2022, the Company amended the Credit Agreement and the Note to extend the due date by one year to March 6, 2023. No other terms of the Note were changed as a part of the extension. The Company performed a debt extinguishment vs. modification analysis. The analysis determined that the extension would be considered an extinguishment from an accounting standpoint, due to the change in the value of the conversion option. However, no gain or loss was recorded to the consolidated statement of operations for the quarter ended March 31, 2022 as it was determined that the fair value of the Note was $10,000,000 both before and after the extension.
Boyalife Genomics
On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based contract development and manufacturing organization (“CDMO”) and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a newly formed division named TG Biosynthesis.
Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the quarter ended March 31, 2022, 0 royalty payments were made to Boyalife Genomics.
Z3 Investment
Also on March 24, 2022, the Company entered into a five year Lease Agreement with Z3 Investment LLC, an affiliate of the Company’s Chairman and CEO, beginning April 1, 2022, for approximately 35,475 square feet of laboratory and office space in Rancho Cordova, California. Under the terms of the agreement, monthly rent will be $46,000 per month for the firstsix months, then increasing to $104,000 per month (with a 4% annual increase) thereafter.
3.5. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESConvertible Promissory Note
There have been noJuly 2019 material changesNote
On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s significant accounting policiescommon stock on the date of conversion (subject to those discloseda floor conversion price of $0.50). The July 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the Company’s Annual Report filed on its Formmanner described below, all principal under the 10-K for the year ended December 31, 2020.
Recently Adopted Accounting Standards
In DecemberJuly 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting of Income Taxes”, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. The Company was not profitable for the six months ended June 30, 2021 and has a full valuation allowance on all net operating loss (“NOL”) tax carryforwards. As such, the adoption of this standard did not have a material impact on the Company’s financial statements.
In January 2020, the FASB issued ASU 2020-01, “Investments – Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815”. The new guidance clarifies the interaction of accounting for the transition into and outdate of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. It is effective for fiscal years beginning afterissuance on December 15, 2020, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s financial statements.
Revenue Recognition
Revenue is recognized based on the five-step process outlined in Accounting Standards Codification (“ASC”) 606.July 31, 2022.
The following tables summarize the revenues by product line:
| | | Three Months Ended June 30, 2021 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 1,048,000 | | | $ | 48,000 | | | $ | -- | | | $ | 1,096,000 | |
BioArchive | | | 223,000 | | | | 326,000 | | | | -- | | | | 549,000 | |
CAR-TXpress | | | 287,000 | | | | 30,000 | | | | 72,000 | | | | 389,000 | |
Manual Disposables | | | 116,000 | | | | -- | | | | -- | | | | 116,000 | |
Other | | | 30,000 | | | | -- | | | | 21,000 | | | | 51,000 | |
Total | | $ | 1,704,000 | | | $ | 404,000 | | | $ | 93,000 | | | $ | 2,201,000 | |
| | | Six Months Ended June 30, 2021 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 1,273,000 | | | $ | 87,000 | | | $ | -- | | | $ | 1,360,000 | |
BioArchive | | | 431,000 | | | | 868,000 | | | | -- | | | | 1,299,000 | |
CAR-TXpress | | | 542,000 | | | | 58,000 | | | | 143,000 | | | | 743,000 | |
Manual Disposables | | | 245,000 | | | | -- | | | | -- | | | | 245,000 | |
Other | | | 37,000 | | | | -- | | | | 34,000 | | | | 71,000 | |
Total | | $ | 2,528,000 | | | $ | 1,013,000 | | | $ | 177,000 | | | $ | 3,718,000 | |
| | | Three Months Ended June 30, 2020 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 621,000 | | | $ | 48,000 | | | $ | -- | | | $ | 669,000 | |
BioArchive | | | 165,000 | | | | 294,000 | | | | -- | | | | 459,000 | |
CAR-TXpress | | | 550,000 | | | | 13,000 | | | | 71,000 | | | | 634,000 | |
Manual Disposables | | | 198,000 | | | | -- | | | | -- | | | | 198,000 | |
Other | | | 238,000 | | | | -- | | | | 44,000 | | | | 282,000 | |
Total | | $ | 1,772,000 | | | $ | 355,000 | | | $ | 115,000 | | | $ | 2,242,000 | |
The following summarizes the July 2019 Note:
| | | Six Months Ended June 30, 2020 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 2,829,000 | | | $ | 72,000 | | | $ | -- | | | $ | 2,901,000 | |
BioArchive | | | 329,000 | | | | 626,000 | | | | -- | | | | 955,000 | |
CAR-TXpress | | | 702,000 | | | | 25,000 | | | | 142,000 | | | | 869,000 | |
Manual Disposables | | | 401,000 | | | | -- | | | | -- | | | | 401,000 | |
Other | | | 252,000 | | | | -- | | | | 64,000 | | | | 316,000 | |
Total | | $ | 4,513,000 | | | $ | 723,000 | | | $ | 206,000 | | | $ | 5,442,000 | |
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 7/31/2022 | | | 24 | % | | $ | 0.61 | | | $ | 1,000,000 | |
At December 31, 2021 | 7/31/2022 | | | 24 | % | | $ | 0.91 | | | $ | 813,000 | |
Amortization of debt discount on the July 2019 Note was $0 and $80,000 for the three months ended March 31, 2022 and 2021, respectively. Interest expense related to the July 2019 Note was $60,000 for both the quarters ended March 31, 2022 and 2021.
6. Stockholders’ Equity
Common Stock
On February 3, 2022, the Company entered into Amendment No.2 to the At the Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC to further increase the maximum aggregate offering price of shares of Common Stock that may be offered and sold from time to time under the Offering Agreement from $15,280,313 to $19,555,261, which enables the Company to sell an additional $4,275,000 of shares after taking into account prior sales under the Offering Agreement (the “Additional Shares”). Amendment No.2 also amended the Offering Agreement to change the expiration date of the Offering Agreement from August 9, 2022 to the date on which all of the Additional Shares are sold by the Company or until the Offering Agreement is otherwise mutually terminated, subject to the early termination provisions set forth in the agreement. The terms and conditions of the Offering Agreement otherwise remain unchanged. The Company sold a total of 918,093 shares of common stock under the Offering Agreement for aggregate gross proceeds of $681,000 at an average selling price of $0.74 per share, resulting in net proceeds of approximately $594,000 after deducting commissions and other transaction costs of approximately $87,000.
Equity Plans
On January 13, 2022, the Company’s stockholders approved an amendment of the Company’s Amended 2016 Equity Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 392,500 shares to 1,200,000 shares.
Net Loss Per Share
Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31:
| | | 2022 | | | 2021 | |
Common stock equivalents of convertible promissory note and accrued interest | | | 17,420,222 | | | | 6,449,950 | |
Warrants – other | | | 653,248 | | | | 653,248 | |
Stock options | | | 342,670 | | | | 889,636 | |
Total | | | 18,416,140 | | | | 7,992,834 | |
7. Revenue
The following table summarizes the revenues by product line and type:
| | | Three Months Ended March 31, 2022 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 1,711,000 | | | $ | 55,000 | | | $ | -- | | | $ | 1,766,000 | |
BioArchive | | | 155,000 | | | | 298,000 | | | | -- | | | | 453,000 | |
CAR-TXpress | | | 199,000 | | | | 43,000 | | | | 71,000 | | | | 313,000 | |
Manual Disposables | | | 105,000 | | | | -- | | | | -- | | | | 105,000 | |
Other | | | 17,000 | | | | -- | | | | 9,000 | | | | 26,000 | |
Total | | $ | 2,187,000 | | | $ | 396,000 | | | $ | 80,000 | | | $ | 2,663,000 | |
| | | Three Months Ended March 31, 2021 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 225,000 | | | $ | 39,000 | | | $ | -- | | | $ | 264,000 | |
BioArchive | | | 208,000 | | | | 542,000 | | | | -- | | | | 750,000 | |
CAR-TXpress | | | 255,000 | | | | 28,000 | | | | 71,000 | | | | 354,000 | |
Manual Disposables | | | 129,000 | | | | -- | | | | -- | | | | 129,000 | |
Other | | | 7,000 | | | | -- | | | | 13,000 | | | | 20,000 | |
Total | | $ | 824,000 | | | $ | 609,000 | | | $ | 84,000 | | | $ | 1,517,000 | |
Contract Balances
Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the three and sixmonths ended June 30, 2021March 31, 2022 that were included in the beginning balance of deferred revenue were $130,000 and $403,000, respectively.$446,000. Short-term deferred revenues increased from $608,000 to $903,000were $1,159,000 and long-term$719,000 at March 31, 2022 and December 31, 2021, respectively. Long-term deferred revenues decreased from $1,596,000 to $1,442,000 during therevenue was $1,163,000 and $1,244,000 at sixMarch 31, 2022 months endedand June 30,December 31, 2021, respectively.
Exclusivity Fee
On August 30, 2019, the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of five years with Corning having two options to renew for an additional two-years (up to four years total), unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted Corning exclusive worldwide distribution rights for substantially all X-Series® products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. In addition to any amounts payable throughout the Term for the Products, as consideration for the exclusive worldwide distribution rights for the Products, Corning paid a $2,000,000 exclusivity fee. For the three and six months ended June 30, 2021 and 2020, the Company recorded revenue related to the exclusivity fee of $72,000 and $143,000, respectively. The remaining balance of the $2,000,000 payment of $1,477,000 was recorded to deferred revenue, with $286,000 in short term deferred revenue and $1,191,000 recorded in long-term deferred revenue.
BacklogConvertible Promissory Note and Revolving Credit Agreement
In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of Remaining Customer Performance Obligationsthe Boyalife Group (USA), Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). As of December 31, 2021, the Company had an outstanding principal balance on the Loan of $10,000,000. On March 4, 2022, the Company amended the Loan extending the Maturity Date by one year to March 6, 2023.
The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Loan can be prepaid in whole or in part by the Company at any time without penalty.
The following tablesummarizes the Note:
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 3/6/2023 | | | 22 | % | | $ | 0.64 | | | $ | 10,000,000 | |
At December 31, 2021 | 3/6/2022 | | | 22 | % | | $ | 1.80 | | | $ | 9,245,000 | |
The Note includes revenue expecteda down round provision that lowers its conversion price if the Company sells shares of common stock at a lower price per share. In February 2022, the Company sold shares of common stock at a price lower than the conversion price of the Note, resulting in a down round triggering event lowering the conversion price of the Note to be recognized$0.64 per share. The Company determined that the triggering event created incremental value of $213,000 which was treated as a debt discount and recorded as salesamortized over the remaining term of the Note. A Black-Scholes pricing model was utilized to determine the change in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the endbefore and after incremental value of the reporting period.conversion option with the following inputs:
| | | Remainder of 2021 | | | 2022 | | | 2023 | | | 2024 | | | 2025 and beyond | | | Total | |
Service revenue | | $ | 690,000 | | | $ | 886,000 | | | $ | 412,000 | | | $ | 151,000 | | | $ | 85,000 | | | $ | 2,224,000 | |
Clinical revenue | | | 6,000 | | | | 13,000 | | | | 13,000 | | | | 13,000 | | | | 160,000 | | | | 205,000 | |
Exclusivity fee | | | 143,000 | | | | 286,000 | | | | 286,000 | | | | 286,000 | | | | 476,000 | | | | 1,477,000 | |
Total | | $ | 839,000 | | | $ | 1,185,000 | | | $ | 711,000 | | | $ | 450,000 | | | $ | 721,000 | | | $ | 3,906,000 | |
| | | Before | | | After | |
Conversion Price | | $ | 1.80 | | | $ | 0.64 | |
Term (in years) | | | 0.02 | | | | 0.02 | |
Volatility | | | 39.53 | % | | | 39.53 | % |
Dividend rate | | | 0 | % | | | 0 | % |
Risk free rate | | | 1.97 | % | | | 1.97 | % |
Revenues are netThe Company amortized $213,000 and $827,000 of normal discounts. Shipping and handling fees billeddebt discount to customers are included in net revenues, while the related costs are included in cost of revenues.
Reclassifications
Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not have an impact on net loss as previously reported. Forinterest expense for the three months ended March 31, 2022 and2021, respectively. In addition to the amortization, the Company also recorded interest expense of $550,000 for each of the quarters ended March 31, 2022 and 2021. The interest payable balance as of March 31, 2022 and December 31, 2021 was $153,000 and $2,231,000, respectively.
On March 4, 2022, the Company amended the Credit Agreement and the Note to extend the due date by one year to March 6, 2023. No other terms of the Note were changed as a part of the extension. The Company performed a debt extinguishment vs. modification analysis. The analysis determined that the extension would be considered an extinguishment from an accounting standpoint, due to the change in the value of the conversion option. However, no gain or loss was recorded to the consolidated statement of operations for the quarter ended March 31, 2022 as it was determined that the fair value of the Note was $10,000,000 both before and after the extension.
Boyalife Genomics
On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based contract development and manufacturing organization (“CDMO”) and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a newly formed division named TG Biosynthesis.
Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the quarter ended March 31, 2022, 0 royalty payments were made to Boyalife Genomics.
Z3 Investment
Also on March 24, 2022, the Company entered into a five year Lease Agreement with Z3 Investment LLC, an affiliate of the Company’s Chairman and CEO, beginning April 1, 2022, for approximately 35,475 square feet of laboratory and office space in Rancho Cordova, California. Under the terms of the agreement, monthly rent will be $46,000 per month for the first six months, then increasing to $104,000 per month period ended June 30, 2021, sales and marketing and general and administrative expenses were combined into one line item identified as sales, general and administrative expenses on the Statement of Operations. Additionally, the loss on equity method investments was combined with other income on the Statement of Operations.
(with a 4% annual increase) thereafter.
4.5. Convertible Promissory Note
July 2019 Note
On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on July 31, 2022.
The following summarizes the July 2019 Note:
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 7/31/2022 | | | 24 | % | | $ | 0.61 | | | $ | 1,000,000 | |
At December 31, 2021 | 7/31/2022 | | | 24 | % | | $ | 0.91 | | | $ | 813,000 | |
Amortization of debt discount on the July 2019 Note was $0 and $80,000 for the three months ended March 31, 2022 and 2021, respectively. Interest expense related to the July 2019 Note was $60,000 for both the quarters ended March 31, 2022 and 2021.
NET LOSS PER SHARE6. Stockholders’ Equity
Common Stock
On February 3, 2022, the Company entered into Amendment No.2 to the At the Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC to further increase the maximum aggregate offering price of shares of Common Stock that may be offered and sold from time to time under the Offering Agreement from $15,280,313 to $19,555,261, which enables the Company to sell an additional $4,275,000 of shares after taking into account prior sales under the Offering Agreement (the “Additional Shares”). Amendment No.2 also amended the Offering Agreement to change the expiration date of the Offering Agreement from August 9, 2022 to the date on which all of the Additional Shares are sold by the Company or until the Offering Agreement is otherwise mutually terminated, subject to the early termination provisions set forth in the agreement. The terms and conditions of the Offering Agreement otherwise remain unchanged. The Company sold a total of 918,093 shares of common stock under the Offering Agreement for aggregate gross proceeds of $681,000 at an average selling price of $0.74 per share, resulting in net proceeds of approximately $594,000 after deducting commissions and other transaction costs of approximately $87,000.
Equity Plans
On January 13, 2022, the Company’s stockholders approved an amendment of the Company’s Amended 2016 Equity Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 392,500 shares to 1,200,000 shares.
Net Loss Per Share
Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no vesting or other contingencies associated with them. As of June 30, 2021, all pre-funded warrants previously issued have been exercised and none are currently outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30:March 31:
| | | 2021 | | | 2020 | | | 2022 | | | 2021 | |
Common stock equivalents of convertible promissory note and accrued interest | | 6,758,897 | | | 6,676,112 | | | 17,420,222 | | | 6,449,950 | |
Vested Series A warrants | | -- | | | 40,441 | | |
Unvested Series A warrants(1) | | -- | | | 69,853 | | |
Warrants – other | | 653,248 | | | 1,006,190 | | | 653,248 | | | 653,248 | |
Stock options | | | 386,461 | | | | 893,349 | | | | 342,670 | | | | 889,636 | |
Total | | | 7,798,606 | | | | 8,685,945 | | | | 18,416,140 | | | | 7,992,834 | |
| (1)
| The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021.
|
5.7.RELATED PARTY TRANSACTIONS Revenue
HealthBanks Biotech (USA) Inc.The following table summarizes the revenues by product line and type:
On
| | | Three Months Ended March 31, 2022 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 1,711,000 | | | $ | 55,000 | | | $ | -- | | | $ | 1,766,000 | |
BioArchive | | | 155,000 | | | | 298,000 | | | | -- | | | | 453,000 | |
CAR-TXpress | | | 199,000 | | | | 43,000 | | | | 71,000 | | | | 313,000 | |
Manual Disposables | | | 105,000 | | | | -- | | | | -- | | | | 105,000 | |
Other | | | 17,000 | | | | -- | | | | 9,000 | | | | 26,000 | |
Total | | $ | 2,187,000 | | | $ | 396,000 | | | $ | 80,000 | | | $ | 2,663,000 | |
| | | Three Months Ended March 31, 2021 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 225,000 | | | $ | 39,000 | | | $ | -- | | | $ | 264,000 | |
BioArchive | | | 208,000 | | | | 542,000 | | | | -- | | | | 750,000 | |
CAR-TXpress | | | 255,000 | | | | 28,000 | | | | 71,000 | | | | 354,000 | |
Manual Disposables | | | 129,000 | | | | -- | | | | -- | | | | 129,000 | |
Other | | | 7,000 | | | | -- | | | | 13,000 | | | | 20,000 | |
Total | | $ | 824,000 | | | $ | 609,000 | | | $ | 84,000 | | | $ | 1,517,000 | |
Contract Balances
Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does November 26, 2019 not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the Company entered into an agreement with HealthBanks Biotech (USA) Inc. (“HealthBanks”) to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercializeconsolidated balance sheet). Revenues recognized during the Company’s proprietary cell processing platform, CAR-TXpress™, for usethree months ended March 31, 2022 that were included in immune cell banking as well as for cell-based contract developmentthe beginning balance of deferred revenue were $446,000. Short-term deferred revenues were $1,159,000 and manufacturing services (CMO/CDMO). Under the terms of the agreement, ImmuneCyte$719,000 at March 31, 2022 and December 31, 2021, respectively. Long-term deferred revenue was initially owned 80% by HealthBanks$1,163,000 and 20% by the Company. Healthbanks is a subsidiary of the Boyalife Group (USA), Inc. which is owned by Dr. Xiaochun (Chris) Xu, the Company’s Chief Executive Officer $1,244,000 at March 31, 2022 and Chairman of our Board of Directors. Due to the significant influence the Company has over ImmuneCyte’s operations, the investment was accounted for by the Company using the equity method.December 31, 2021, respectively.
Between November 26, 2019 and September 30, 2020, ImmuneCyte closed on a series of investments with a private institution and qualified investors. After the investments, ImmuneCyte was owned 75.16% by HealthBanks, 18.79% by the Company and 6.05% by the private investors.
In March 2021, ImmuneCyte completed an acquisition to acquire Boyalife’s Cellular Therapy Division, for 12,000,000 shares in ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. For 500,000 shares in ImmuneCyte. Following the acquisitions, the Company’s ownership percentage in ImmuneCyte decreased from 18.79% to 8.64%. The Company performed an analysis of the transaction and noted that none of the factors supporting significant influence changed as a result of the acquisition. Therefore, it was concluded that significant influence remains and the Company will continue to account for the transaction using the equity method. The Company recognized a dilution gain of $262,000 representing its share of the net assets acquired by ImmuneCyte. However, at the time of the acquistion, the Company had accumulated losses of $428,000 in its investment in ImmuneCyte. As the accumulated losses were greater than the dilution gain, no entry was recorded by the Company for its investment in ImmuneCyte for the quarter ended March 31, 2021.
As of June 30, 2021, the value of the Company’s investment in ImmuneCyte on its Balance Sheet is $0. For the quarter ended June 30, 2021, ImmuneCyte had a net income of $599,000, its current assets were $3,753,000 and current liabilities were $2,013,000.
Convertible Promissory Note and Revolving Credit Agreement
In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of the Boyalife Group (USA), Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). As of June 30, 2021 and December 31, 2020,2021, the Company had an outstanding principal balance on the Loan of $10,000,000. On March 4, 2022, the Company amended the Loan extending the Maturity Date by one year to March 6, 2023.
The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. In January 2021, the Company paid the Lender, the interest due as of December 31, 2020 in the amount of $2,082,000. The NoteLoan can be prepaid in whole or in part by the Company at any time without penalty.
The Credit Agreement and Note were amended in April 2018, granting the Lender the right to convert, at any time, outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price of $16.10 per share. The amendment included a down-round provision that lowered the conversion price if the Company issues shares of common stock at a lower price per share, the conversion price of the Note is lowered to that amount. The Company completed a transaction in 2018, which lowered the conversion price to $1.80.
The following summarizes the Note:
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Face Value | | | Remaining Debt Discount | | | Carrying Value | |
At June 30, 2021 | 3/6/2022 | | | 22 | % | | $ | 1.80 | | | $ | 10,000,000 | | | $ | (2,410,000 | ) | | $ | 7,590,000 | |
At December 31, 2020 | 3/6/2022 | | | 22 | % | | $ | 1.80 | | | $ | 10,000,000 | | | $ | (4,065,000 | ) | | $ | 5,935,000 | |
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 3/6/2023 | | | 22 | % | | $ | 0.64 | | | $ | 10,000,000 | |
At December 31, 2021 | 3/6/2022 | | | 22 | % | | $ | 1.80 | | | $ | 9,245,000 | |
The Note includes a down round provision that lowers its conversion price if the Company sells shares of common stock at a lower price per share. In February 2022, the Company sold shares of common stock at a price lower than the conversion price of the Note, resulting in a down round triggering event lowering the conversion price of the Note to $0.64 per share. The Company determined that the triggering event created incremental value of $213,000 which was treated as a debt discount and amortized over the remaining term of the Note. A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option with the following inputs:
| | | Before | | | After | |
Conversion Price | | $ | 1.80 | | | $ | 0.64 | |
Term (in years) | | | 0.02 | | | | 0.02 | |
Volatility | | | 39.53 | % | | | 39.53 | % |
Dividend rate | | | 0 | % | | | 0 | % |
Risk free rate | | | 1.97 | % | | | 1.97 | % |
The Company amortized $827,000$213,000 and $1,655,000$827,000 of debt discount to interest expense for the three and sixmonths ended June 30, 2021March 31, 2022 and $729,000 and $1,276,000 for the three2021, and six months ended June 30 2020, respectively. In addition to the amortization, the Company also recorded interest expense of $556,000 and $1,106,000$550,000 for each of the quarters ended threeMarch 31, 2022 and six2021. months ended June 30, 2021 and $515,000 and $957,000 for the three and six months ended June 30 2020, respectively. The interest payable balance as of June 30, 2021March 31, 2022 and December 31, 20202021 was $1,106,000$153,000 and $2,082,000,$2,231,000, respectively.
On March 4, 2022, the Company amended the Credit Agreement and the Note to extend the due date by one year to March 6, 2023. No other terms of the Note were changed as a part of the extension. The Company performed a debt extinguishment vs. modification analysis. The analysis determined that the extension would be considered an extinguishment from an accounting standpoint, due to the change in the value of the conversion option. However, no gain or loss was recorded to the consolidated statement of operations for the quarter ended March 31, 2022 as it was determined that the fair value of the Note was $10,000,000 both before and after the extension.
Boyalife Genomics
On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based contract development and manufacturing organization (“CDMO”) and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a newly formed division named TG Biosynthesis.
Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the quarter ended March 31, 2022, 0 royalty payments were made to Boyalife Genomics.
Z3 Investment
Also on March 24, 2022, the Company entered into a five year Lease Agreement with Z3 Investment LLC, an affiliate of the Company’s Chairman and CEO, beginning April 1, 2022, for approximately 35,475 square feet of laboratory and office space in Rancho Cordova, California. Under the terms of the agreement, monthly rent will be $46,000 per month for the firstsix months, then increasing to $104,000 per month (with a 4% annual increase) thereafter.
6.5. CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note
July 2019 Note
On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on July 31, 2022.
The following summarizes the July 2019 Note:
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Face Value | | | Remaining Debt Discount | | | Carrying Value | |
At June 30, 2021 | 7/31/2022 | | | 24 | % | | $ | 1.80 | | | $ | 1,000,000 | | | $ | (347,000 | ) | | $ | 653,000 | |
At December 31, 2020 | 7/31/2022 | | | 24 | % | | $ | 1.80 | | | $ | 1,000,000 | | | $ | (507,000 | ) | | $ | 493,000 | |
The Company recorded amortization expense for the debt discount on the July 2019 Note for the three and six months ended June 30, 2021 of $80,000 and $161,000, respectively; and $27,000 for the three and six months ended June 30, 2020. Interest expense related to the July 2019 Note was $60,000 and $120,000 for the three and six months ended June 30, 2021 and 2020.
7.LEASES
The Company leases an approximately 28,000 square foot facility located in Rancho Cordova, California for its corporate offices and in-house manufacturing. The lease was renewed in the first quarter of 2019 and is accounted for as an operating lease. The lease expires in May 2024.
Operating Leases
Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. Our material leases typically contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term.
The following summarizes the Company’s operating leases:July 2019 Note:
| | | June 30, 2021 | | | December 31, 2020 | |
Right-of-use operating lease assets, net | | $ | 654,000 | | | $ | 730,000 | |
Current lease liability (included in other current liabilities) | | | 180,000 | | | | 157,000 | |
Non-current lease liability | | | 508,000 | | | | 604,000 | |
| | | | | | | | | |
Weighted average remaining lease term | | | 2.9 | | | | 3.4 | |
Discount rate | | | 22 | % | | | 22 | % |
| | Maturity Date | | Stated Interest Rate | | | Conversion Price | | | Carrying Value | |
At March 31, 2022 | 7/31/2022 | | | 24 | % | | $ | 0.61 | | | $ | 1,000,000 | |
At December 31, 2021 | 7/31/2022 | | | 24 | % | | $ | 0.91 | | | $ | 813,000 | |
MaturitiesAmortization of lease liabilities by year for our operating leases are as follows:
2021 (Remaining) | | $ | 157,000 | |
2022 | | | 319,000 | |
2023 | | | 328,000 | |
2024 | | | 139,000 | |
Total lease payments | | $ | 943,000 | |
Less: imputed interest | | | (255,000 | ) |
Present value of operating lease liabilities | | $ | 688,000 | |
Statement of Cash Flows
In January 2019, the Company signed an amendment to its Rancho Cordova, California lease. The amendment was accounted for as a modification and resulted in a right-of-use asset of $966,000 being recognized as a non-cash additiondebt discount on the date of the amendment. Cash paid for amounts included in the measurement of operating lease liabilities included in cash flow from operating activitiesJuly 2019 Note was $77,000$0 and $153,000$80,000 for the three and sixmonths ended June 30, 2021March 31, 2022 and $75,000 and $149,000 for2021, respectively. Interest expense related to the threeJuly 2019 and six monthsNote was $60,000 for both the quarters ended June 30, 2020, respectively.
Operating Lease Costs
Operating lease costs were $110,000 and $219,000 for the three and six months ended June 30, 2021 and $105,000 and $208,000 for the three and six months ended June 30, 2020, respectively. These costs are primarily related to long-term operating leases, but also include amounts for variable lease costs, as well as immaterial and short-term leases.
Finance Leases
Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases were not material for the three and six months ended June 30, 2021March 31, 2022 and 2020.2021.
8.6. Stockholders’COMMITMENTS AND CONTINGENCIES Equity
Contingencies
In the normal course of operations, the Company may have disagreements or disputes with customers, employees or vendors. Such potential disputes are seen by management as a normal part of business. As of June 30, 2021, except as disclosed, management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s condensed consolidated financial position, operating results or cash flows.
Financial Covenants
On July 13, 2020, the Company, entered into a Manufacturing and Supply Amending Agreement #2 with CBR Systems, Inc. (“CBR”) with an effective date of July 13, 2020 (the “Amendment”). The Amendment amends the Manufacturing and Supply Agreement entered into on May 15, 2017 and Amendment #1 dated March 16, 2020 by the Company and CBR. The Amendment, among other things, revised the amount of certain products to be purchased, pricing of those products and removal of the safety stock requirement. In addition, the Amendment updated the financial requirement to exclude convertible debt from the definition of short-term debt under events or conditions that constitute a default. The Amendment states that the Company’s cash balance and short-term investments net of non-convertible debt and borrowed funds that are payable within one year must be greater than $1,000,000 at any month end. The Company was in compliance with this agreement as of June 30, 2021.
Warranty
The Company offers a warranty on all of its non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.
The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the six months ended June 30, 2021 is summarized in the following table:
Balance at December 31, 2020 | | $ | 154,000 | |
Warranties issued during the period | | | 21,000 | |
Settlements made during the period | | | (75,000 | ) |
Changes in liability for pre-existing warranties during the period | | | -- | |
Balance at June 30, 2021 | | $ | 100,000 | |
9.PAYMENT PROTECTION PROGRAM
On April 21, 2020, the Company entered into a promissory note and received a Paycheck Protection Program loan “PPP Loan” from the Small Business Association “SBA”, which was established under the CARES Act. The Company received net proceeds of $646,000 from the PPP Loan. The term of the PPP Loan is two years with an interest rate of 1.00% per annum, which was deferred for the firstsix months of the term of the loan or after an application is filed for loan forgiveness, whichever is later. Each monthly payment shall be in the amount which would fully amortize the principal balance outstanding under the PPP Loan. Pursuant to the terms of the CARES Act, the proceeds of the PPP Loan may be used for payroll costs, mortgage interest, rent or utility costs. The promissory note of the PPP Loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in a claim for the immediate repayment of the amount outstanding under the PPP Loan. In late December 2020, the Company applied with the SBA for forgiveness of the PPP Loan and was notified on March 30, 2021 that the SBA had approved our application to forgive the entire amount of the loan and accrued interest. For the six months ended June 30, 2021, the Company recorded a gain on extinguishment of debt of $652,000 representing the principal and accrued interest for the PPP Loan at the time of forgiveness.
10.STOCKHOLDERS’ EQUITY
Common Stock
On December 13, 2019,February 3, 2022, the Company entered into anAmendment No.2 to the At Thethe Market Offering Agreement by and between the Company and(the “Offering Agreement”) with H.C. Wainwright & Co., LLC as agent (“H.C. Wainwright”) (the “ATM Agreement”), pursuant to whichfurther increase the Companymaximum aggregate offering price of shares of Common Stock that may offerbe offered and sell,sold from time to time through H.C. Wainwright,under the Offering Agreement from $15,280,313 to $19,555,261, which enables the Company to sell an additional $4,275,000 of shares after taking into account prior sales under the Offering Agreement (the “Additional Shares”). Amendment No.2 also amended the Offering Agreement to change the expiration date of the Company’s common stock, having an aggregate offering priceOffering Agreement from August 9, 2022 to the date on which all of upthe Additional Shares are sold by the Company or until the Offering Agreement is otherwise mutually terminated, subject to $4,400,000the early termination provisions set forth in the agreement. The terms and on May 19, 2020 conditions of the ATMOffering Agreement was amended to increase the aggregate value of up to $15,280,313 (the “HCW Shares”). As of June 30, 2021, theotherwise remain unchanged. The Company sold a total of 5,597,484918,093 shares of the Company’s common stock under the Offering Agreement for aggregate gross proceeds of $15,280,000$681,000 at an average selling price of $2.73$0.74 per share, resulting in net proceeds of approximately $14,568,000$594,000 after deducting legal expenses, audit fees, commissions and other transaction costs of approximately $712,000. For the six months ended June 30, 2021, the Company sold 2,976,832 shares of common stock for net proceeds of $6,832,000 after deducting $224,000 in commissions and other transaction costs.$87,000.
Equity Plans
On January 13, 2022, the Company’s stockholders approved an amendment of the Company’s Amended 2016 Equity Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 392,500 shares to 1,200,000 shares.
Net Loss Per Share
Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31:
| | | 2022 | | | 2021 | |
Common stock equivalents of convertible promissory note and accrued interest | | | 17,420,222 | | | | 6,449,950 | |
Warrants – other | | | 653,248 | | | | 653,248 | |
Stock options | | | 342,670 | | | | 889,636 | |
Total | | | 18,416,140 | | | | 7,992,834 | |
Stock Based Compensation7. Revenue
InThe following table summarizes the revenues by product line and type:
| | | Three Months Ended March 31, 2022 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 1,711,000 | | | $ | 55,000 | | | $ | -- | | | $ | 1,766,000 | |
BioArchive | | | 155,000 | | | | 298,000 | | | | -- | | | | 453,000 | |
CAR-TXpress | | | 199,000 | | | | 43,000 | | | | 71,000 | | | | 313,000 | |
Manual Disposables | | | 105,000 | | | | -- | | | | -- | | | | 105,000 | |
Other | | | 17,000 | | | | -- | | | | 9,000 | | | | 26,000 | |
Total | | $ | 2,187,000 | | | $ | 396,000 | | | $ | 80,000 | | | $ | 2,663,000 | |
| | | Three Months Ended March 31, 2021 | |
| | | Device Revenue | | | Service Revenue | | | Other Revenue | | | Total Revenue | |
AXP | | $ | 225,000 | | | $ | 39,000 | | | $ | -- | | | $ | 264,000 | |
BioArchive | | | 208,000 | | | | 542,000 | | | | -- | | | | 750,000 | |
CAR-TXpress | | | 255,000 | | | | 28,000 | | | | 71,000 | | | | 354,000 | |
Manual Disposables | | | 129,000 | | | | -- | | | | -- | | | | 129,000 | |
Other | | | 7,000 | | | | -- | | | | 13,000 | | | | 20,000 | |
Total | | $ | 824,000 | | | $ | 609,000 | | | $ | 84,000 | | | $ | 1,517,000 | |
Contract Balances
Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does May 2021, fivenot Company executives voluntarily surrenderedhave any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the options they were awarded in June 2020. At the time they were surrendered, the exercise price of the options was underwater. No payment or other consideration was paid to the Company executives for surrendering the options. In total 490,000 options were cancelled. As a result of the cancellation, the remaining unamortized expense of $2,008,000 was accelerated and recorded inconsolidated balance sheet). Revenues recognized during the three months ended June 30, 2021.March 31, 2022
The Company recorded stock-based compensationthat were included in the beginning balance of $2,099,000deferred revenue were $446,000. Short-term deferred revenues were $1,159,000 and $2,357,000 for the$719,000 at threeMarch 31, 2022 and six months ended June 30,December 31, 2021, respectively. Long-term deferred revenue was $1,163,000 and $314,000 and $381,000 for the$1,244,000 at threeMarch 31, 2022 and sixDecember 31, 2021, months ended June 30, 2020, respectively, as comprised of the following:respectively.
| | | Three Months Ended June 30, | | | Six Months Ended June 30, | |
| | | 2021 | | | 2020 | | | 2021 | | | 2020 | |
Cost of revenues | | $ | 5,000 | | | $ | 2,000 | | | $ | 10,000 | | | $ | 2,000 | |
Selling, general and administrative | | | 1,914,000 | | | | 291,000 | | | | 2,130,000 | | | | 343,000 | |
Research and development | | | 180,000 | | | | 21,000 | | | | 217,000 | | | | 36,000 | |
| | | $ | 2,099,000 | | | $ | 314,000 | | | $ | 2,357,000 | | | $ | 381,000 | |
The following is a summary of option activity for the Company’s stock option plans:
| | | Number of Shares | | | Weighted- Average Exercise Price | | | Weighted- Average Remaining Contractual Life | | | Aggregate Intrinsic Value | |
Outstanding at December 31, 2020 | | | 889,636 | | | $ | 8.57 | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
Cancelled / Forfeited | | | 503,050 | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
Outstanding at June 30, 2021 | | | 386,461 | | | $ | 11.88 | | | | 7.4 | | | $ | -- | |
| | | | | | | | | | | | | | | | | |
Vested and expected to vest at June 30, 2021 | | | 335,786 | | | $ | 9.15 | | | | 7.3 | | | $ | -- | |
| | | | | | | | | | | | | | | | | |
Exercisable at June 30, 2021 | | | 244,211 | | | $ | 10.31 | | | | 7.1 | | | $ | -- | |
Backlog of Remaining Customer Performance Obligations
The aggregate intrinsic value is calculated asfollowing table represents revenue expected to be recognized in the difference betweenfuture from the exercise pricebacklog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the underlying awards and the quoted price of the Company’s common stock. There were 0 options exercised during the six months ended June 30, 2021.reporting period:
Warrants
A summary of warrant activity for the six months ended June 30, 2021 is as follows:
| | | Remainder of 2022 | | | 2023 | | | 2024 | | | 2025 | | | 2026 and beyond | | | Total | |
Service revenue | | $ | 1,075,000 | | | $ | 666,000 | | | $ | 184,000 | | | $ | 83,000 | | | $ | -- | | | $ | 2,008,000 | |
Device revenue (1) | | | 712,000 | | | | 733,000 | | | | 41,000 | | | | -- | | | | -- | | | | 1,486,000 | |
Exclusivity fee | | | 214,000 | | | | 286,000 | | | | 286,000 | | | | 286,000 | | | | 190,000 | | | | 1,262,000 | |
| Other | | | 10,000 | | | | 13,000 | | | | 13,000 | | | | 13,000 | | | | 140,000 | | | | 189,000 | |
Total | | $ | 2,011,000 | | | $ | 1,698,000 | | | $ | 524,000 | | | $ | 382,000 | | | $ | 330,000 | | | $ | 4,945,000 | |
| | | Number of Shares | | | Weighted-Average Exercise Price Per Share | | | Weighted- Average Remaining Contract Term | |
Balance at December 31, 2020 | | | 1,116,484 | | | $ | 37.27 | | | | 0.49 | |
Warrants expired | | | 463,236 | | | | | | | | | |
Warrants exercised | | | -- | | | $ | -- | | | | | |
Outstanding at June 30, 2021 | | | 653,248 | | | $ | 6.97 | | | | 1.90 | |
Exercisable at June 30, 2021 | | | 653,248 | | | $ | 6.97 | | | | 1.90 | |
| (1) | Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China. |
11.8.MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE Concentrations
The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable as follows:
For net revenues, one customer accounted for 18% and 0%, a second customer accounted for 16% and 1%, a third customer accounted for 11% and 25% and a fourth customer accounted for 0% and 18% for the three months ended June 30, 2021 and 2020, respectively. For the six months ended June 30, 2021 and 2020,one customer accounted for 13% and 14%, a second customer accounted for 11% and 1%, while a third customer accounted for 11% and 30% of net revenues, respectively.
Accounts Receivable | | March 31, 2022 | | | December 31, 2021 | |
Customer 1 | | | 35 | % | | | -- | |
Customer 2 | | | 16 | % | | | -- | |
Customer 3 | | | 1 | % | | | 23 | % |
Customer 4 | | | 9 | % | | | 23 | % |
At June 30, 2021, 4 customers accounted for 68% of accounts receivable. At December 31, 2020, 3 customers accounted for 72% of accounts receivable.
| | | Three Months Ended March 31, | |
Revenues | | 2022 | | | 2021 | |
Customer 1 | | $ | 1,271,000 | | | | 48 | % | | $ | 151,000 | | | | 10 | % |
Customer 2 | | $ | 2,000 | | | | -- | | | $ | 316,000 | | | | 21 | % |
12.9. SUBSEQUENT EVENTSSubsequent Events
Effective April 1, 2022, the Company entered into a lease for a 35,745 square foot laboratory, office and manufacturing facility in Rancho Cordova, California for its CDMO business. The Company has evaluated events subsequent tolease expires on JuneSeptember 30, 2021 2027.through the date of this filing and determined that no subsequent events have occurred that would require recognition or disclosure in the unaudited condensed consolidated financial statements.
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward‑Looking Statements
This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet U.S. Food and Drug Administration (“FDA”) regulated requirements governing the Company’s products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission (“SEC”), including, in particular, those set forth in Thethe Company’s Form 10-K for the year ended December 31, 2020.2021.
Business Overview
ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA.
The Company providesOur business involves the manufacturing and related service of cell based medical devices, including the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications.large scale cell manufacturing services. The Company and its subsidiaries currently manufacture and market the following products:
Clinical Bio-Banking Applications:
| | ● | AXP® II Automated Cell Separation System – an automated, fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510(k) medical device. |
| | ● | BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510(k) medical device. |
Point-of-Care Applications:
| | ● | PXP® Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics, registered as a U.S. FDA 510(k) medical device. |
| | ● | PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510(k) medical device. |
| | ● | PXP-1000 System – an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination, registered as a U.S. FDA 510(k) medical device. |
Large Scale Cell Processing and Biomanufacturing:
| | ● | X-Series® Products:Products for general laboratory use: X-Lab® for cell isolation, X-Wash® System for cell washing and reformulation, X-Mini® for high efficiency small scale cell purification, and X-BACS® System under development for large scale cell purification using our proprietary buoyancy-activated cell sortingBuoyancy-Activated Cell Sorting (“BACS”) technology. |
| | ● | CAR-TXpress™ Platform for Clinical Manufacturing – a modular designed, functionally closed manufacturing platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing cellular therapies, including chimeric antigen receptor (“CAR”) T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest. |
ThermoGenesis Holdings is an affiliatePlanned Expansion of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technologyBusiness-- Contract Development and cell-based therapeutics.Manufacturing Services for Cell and Cell-Based Gene Therapies
COVID-19
We believe thatIn March 2022, our Board of Directors approved the COVID-19 pandemic has had a material negative impact onplanned expansion of the Company’s business to include contract development and results of operations.manufacturing services for cell and cell-based gene therapies. The pandemic hadCompany plans to develop and build-out the capabilities to become a significant impact onworld-class Contract Development and Manufacturing Organization (“CDMO”) for cell and cell-based gene therapies by partnering with Boyalife Genomics Tianjin Ltd., a China-based CDMO (“Boyalife Genomics”), to in-license certain know-how and other intellectual property from Boyalife Genomics, and by leasing and building out a cell manufacturing facility in Sacramento, California. We intend to leverage our existing technology and combine it with the cord blood industry, with fewer cord blood units being stored globally after the start of the pandemic. The continued impact of the pandemic on the Company’s business and results of operations will depend on future developments relatingin-licensed technologies to the pandemic in general and the cord blood industry in particular, and such future developments are highly uncertain and cannot be predicted. Such developments may include the continued geographic spread of the virus, the severity of the disease, the duration of the outbreak, the actions that may be taken by various governmental authorities in response to the outbreak, and the possible continued impact on the U.S. or global economy. Asdevelop a result, at the time of this filing, it is impossible to predict the continued impact of the pandemic on the Company’s business, liquidity, capital resources and financial results.
Critical Accounting Policies
Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basisproprietary manufacturing platform for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that have been identified as critical in the preparation of the Company’s condensed consolidated financial statements, please refer to ThermoGenesis Holdings’ Form 10-K for the year ended December 31, 2020.
Results of Operations for the Three Months Ended June 30, 2021 as Compared to the Three Months Ended June 30, 2020cell manufacturing activities.
The following tables summarizes revenues by product line:Company plans to develop and operate its planned CDMO business through a newly formed division named TG BiosynthesisTM. It is anticipated that TG Biosynthesis will provide high-quality development and manufacturing capabilities, cell and tissue processing development, quality systems, regulatory compliance, and other cell manufacturing solutions for clients with therapeutic candidates in various stages of development.
| | | Three Months Ended June 30, | | | | | | | | | |
| | | 2021 | | | 2020 | | | $ Change | | | % Change | |
AXP | | $ | 1,096,000 | | | $ | 669,000 | | | $ | 427,000 | | | | 64 | % |
BioArchive | | | 549,000 | | | | 459,000 | | | | 90,000 | | | | 20 | % |
CAR-TXpress | | | 389,000 | | | | 634,000 | | | | (245,000 | ) | | | (39 | )% |
Manual Disposables | | | 116,000 | | | | 198,000 | | | | (82,000 | ) | | | (41 | )% |
Other | | | 51,000 | | | | 282,000 | | | | (231,000 | ) | | | (82 | )% |
Total | | $ | 2,201,000 | | | $ | 2,242,000 | | | $ | (41,000 | ) | | | (2 | )% |
We are targeting the launch of our CDMO services to customers by the end of 2022. The successful development and launch of TG Biosynthesis will require us to raise additional capital, acquire various equipment for the planned operations, hire certain personnel needed to launch the operation, and timely complete the build-out of our leased Sacramento facility. There is no assurance that we will be able to successfully obtain such additional capital resources, as such capital may not be available on reasonable terms, or available at all. We will need to hire, train, and retain additional employees who have experiences in the cell manufacturing field in order for our CDMO business to be successful.
Results of Operations
Three Months Ended March 31, 2022 as Compared to the Three Months Ended March 31, 2021
Net Revenues
Net revenues decreased by $41,000 or 2%, from $2,242,000 to $2,201,000 for the three months ended June 30, 2021 asMarch 31, 2022 were $2,663,000 compared to $1,517,000 for the three months ended June 30, 2020.March 31, 2021, an increase of $1,146,000 or 76%. The declineincrease was primarily driven by CAR-TXpressAXP® disposable sales which decreasedincreased by $245,000 or 39%approximately $1,500,000 with approximately 600 more cases sold in the three months ended June 30, 2021first quarter of 2022 as compared to 2021. The primary driver of the same period in 2020. The declinechange was driven by the COVID-19 pandemic which has limited the Company’s exclusive distributorhad a significant impact on our sales and marketing activities and limited its abilityfirst quarter of 2021. Many of our customers choose not to perform product demosplace new orders for potential new customers. Additionally, Other sales decreased by $231,000 or 82%. This decline was due primarily to COVID-19 antibody testing kits which the Company soldAXP disposables in the three months ended June 30, 2020, but is no longer sellingfirst quarter last year. As we enter the beginning of 2022, AXP sales returned to a more normal level for the first quarter. This increase was offset by a decrease in BioArchive sales, primarily due to approximately $250,000 less in service revenue, as the result of a large one-time service revenue that was recognized in the same period in 2021.first quarter of last year.
These decreases were offset by increases in both the AXP and BioArchive product lines. AXP sales increased by $427,000 or 64% and BioArchive increased by $90,000 or 20% in the three months ended June 30, 2021 as compared to the same period in 2020. We believe this is a positive sign showing that cord blood revenues may be starting to return to pre-pandemic levels. While we don’t have any specific industry data at this time on the number of cord blood units stored globally, AXP disposable sales increased by approximately 150 cases in the second quarter of 2021 as compared to 2020. The increased demand for AXP bagsets appears to imply that global cord blood units stored are beginning to pick up. We currently anticipate this trend continuing and cord blood units stored potentially returning to pre-pandemic levels in the next few quarters.
| | | March 31, 2022 | | | March 31, 2021 | |
AXP | | $ | 1,766,000 | | | $ | 264,000 | |
BioArchive | | | 453,000 | | | | 750,000 | |
CAR-TXpress | | | 313,000 | | | | 354,000 | |
Manual Disposables | | | 105,000 | | | | 129,000 | |
Other | | | 26,000 | | | | 20,000 | |
| | | $ | 2,663,000 | | | $ | 1,517,000 | |
Gross Profit
The Company’s gross profit increased by $3,618,000 to $986,000was $940,000 or 45%35% of net revenues for the three months ended June 30, 2021,March 31, 2022, compared to $(2,632,000)$708,000 or (117)%47% of net revenues for the three months ended June 30, 2020.March 31, 2021, an increase of $232,000. The increase was driven by a one-time expense of approximately $3,600,000 incurred in the three months ended June 30, 2020 of an inventory reserve for the remaining on hand inventory of COVID-19 testing kits at that time. Additionally, the Company had an increase in gross profit from AXPAXP® disposables due to 154 more cases being sold in the three monthsquarter ended June 30, 2021March 31, 2022, resulting in approximately $700,000 more gross profit. This increase was offset by approximately $250,000 less in BioArchive service revenue in the quarter ended March 31, 2022 as compared to the same period in 2020. This increase was offset by a decrease in gross profit from CAR-TXpress, which had sales decline by $245,000 in the same period.2021.
Selling, General and Administrative
Sales, general and administrative expenses for the three months ended June 30, 2021March 31, 2022 were $3,502,000$1,693,000 compared to $1,978,000$1,992,000 for the three months ended June 30, 2020, an increaseMarch 31, 2021, a decrease of $1,524,000$299,000 or 77%15%. The increasedecrease was primarily due to lower stock compensation expense of approximately $200,000 in the quarter ended March 31, 2022, driven by stock compensation expense which increased by approximately $1,600,000 primarily due toincurred in the accelerated expenseprior quarter for the stock optionsawards that were subsequently voluntarily surrendered by Company executives later in the three months ended June 30, 2021. The increase is offset by a decrease of approximately $100,000 due to a fixed asset impairment expense recognized in the three months ended June 30, 2020.
Research2021 and Development Expenses
Consolidated research and development expenses were $622,000 for the three months ended June 30, 2021 as compared to $578,000 for the three months ended June 30, 2020, an increase of $44,000 or 8%. The increase was driven by approximately $150,000 more in stock compensation expense offset by a decrease of approximately $100,000 related to lower salaries and benefits in the three months ended June 30, 2021 as compared to the same period in 2020.
Interest Expense
Interest expense for the three months ended June 30, 2021 was $1,524,000, compared to $1,314,000 for the three months ended June 30, 2020, an increase of $210,000 or 16%. The increase was driven by additional interest expense and amortization of the debt discount related to the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. in the three months ended June 30, 2021 as compared to the same period in 2020.
Results of Operations for the Six Months Ended June 30, 2021 as Compared to the Six Months Ended June 30, 2020
The following tables summarizes revenues by product line:
| | | Six Months Ended June 30, | | | | | | | | | |
| | | 2021 | | | 2020 | | | $ Change | | | % Change | |
AXP | | $ | 1,360,000 | | | $ | 2,901,000 | | | | (1,541,000 | ) | | | (53 | )% |
BioArchive | | | 1,299,000 | | | | 955,000 | | | | 344,000 | | | | 36 | % |
CAR-TXpress | | | 743,000 | | | | 869,000 | | | | (126,000 | ) | | | (14 | )% |
Manual Disposales | | | 245,000 | | | | 401,000 | | | | (156,000 | ) | | | (39 | )% |
Other | | | 71,000 | | | | 316,000 | | | | (245,000 | ) | | | (78 | )% |
Total | | $ | 3,718,000 | | | $ | 5,442,000 | | | $ | (1,724,000 | ) | | | (32 | )% |
Net Revenues
Net revenues decreased by $1,724,000 or 32%, from $3,718,000 to $5,442,000 for the six months ended June 30, 2021 as compared to the six months ended June 30, 2020. The decrease was driven by AXP® disposable sales which declined by approximately $1,600,000 with approximately 900 fewer cases soldno longer outstanding in the first quarter of 2021 as compared to 2020. The primary driver of the decrease was the COVID-19 pandemic which has had a significant impact on our sales since it began over a year ago. We have started to experience increases in sales in the second quarter, which appears to provide evidence that global cord blood units stored may be beginning to pick back up. We currently anticipate this trend continuing and cord blood units stored could be returning to pre-pandemic levels in the next few quarters.
BioArchive sales posted a $344,000 increase in the six months ended June 30, 2021 as compared to the same period in 2020. The increase was driven by higher service revenue in the six months ended June 30, 2021. Offsetting this increase was decreases in the CAR-TXpress and manual disposable primarily as a result of the COVID-19 pandemic. Other revenues also decreased due to COVID-19 testing kits of which the Company didn’t sell in the six months ended June 30, 2021.
Gross Profit
The Company’s gross profit was $1,694,000 or 46% of net revenues for the six months ended June 30, 2021, compared to $(1,140,000) or (21)% for the six months ended June 30, 2020, an increase of $2,834,000. The increase was driven by a lower inventory reserve expense of approximately $3,500,000 in the six months ended June 30, 2021 as compared to the same period in 2020. The inventory reserve recognized in 2020 was primarily for COVID-19 testing kits, which are no longer being sold by the Company. Offsetting the increase was a decrease in gross profit provided by the AXP product line. The six months ended June 30, 2021 had 900 fewer cases of AXP disposables sold as compared to the same period in 2020, resulting in approximately $700,000 less in gross profit.
Selling, General and Administrative
Sales, general and administrative expenses for the six months ended June 30, 2021 were $5,494,000 compared to $4,070,000 for the six months ended June 30, 2020, an increase of $1,424,000 or 35%. The increase was driven by stock compensation expense, which increased by approximately $1,800,000 primarily due to the accelerated expense for the stock options that were voluntarily surrendered by Company executives in the six months ended June 30, 2021. The increase is offset by a decrease of approximately $220,000 due to the absence of legal and other expenses related to the Mavericks lawsuit and approximately $100,000 due to a fixed asset impairment expense incurred in the six months ended June 30, 2020. Additionally, the Company incurred approximately $50,000 in expenses related to its annual stockholder meeting in the six months ended June 30, 2020. In 2021, the Company anticipates moving that meeting to the fourth quarter and expects to incur the expenses later in the year.2022.
Research and Development Expenses
Consolidated researchResearch and development expenses were $1,001,000$456,000 for the sixthree months ended June 30, 2021,March 31, 2022, compared to $1,187,000$379,000 for the sixthree months ended June 30, 2020, a decreaseMarch 31, 2021, an increase of $186,000$77,000 or 16%20%. The decreaseincrease was driven by lowerhigher expenses for salaries and benefits of approximately $225,000 offset by increased project expenses driven by BACS development in the six monthsquarter ended June 30, 2021 as compared to the same period in 2020.March 31, 2022.
Interest Expense
Interest expense decreased to $3,043,000 for the sixthree months ended June 30, 2021March 31, 2022 was $823,000, as compared to $4,845,000$1,519,000 for the sixthree months ended June 30, 2020,March 31, 2021, a decrease of $1,802,000.$696,000 or 46%. The decrease iswas driven an accelerated expenseby lower amortization of $2,486,000 for the unamortized debt discount ofrelated to the beneficial conversion feature associated with the portions of theConvertible Promissory Note and Revolving Credit Agreement with Boyalife Asset Holding II, Inc. which were converted inand the six monthsJuly 2019 Note. In the quarter ended June 30, 2020. This decrease was offset by additionalMarch 31, 2021, the Company recorded amortization of debt discount to interest expense and debt discount amortization of approximately $500,000 relatedfor these convertible notes totaling $906,000, as compared to additional draw down from$213,000 for the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. that occurred in the second quarter of 2020.ended March 31, 2022.
Gain on Extinguishment of Debt
The Company recorded no gain on the extinguishment of debt in the three months ended March 31, 2022 as compared to a gain of $652,000 for the three months ended March 31, 2021. The gain was related to the principal and accrued interest for the Paycheck Protection Program loan the Company received in 2020 and forgiven in March 2021.
Liquidity and Capital Resources
At June 30, 2021,March 31, 2022, the Company had cash and cash equivalents of $8,668,000$3,652,000 and working capital of $4,166,000.($2,283,000). This compares to cash and cash equivalents of $7,161,000$7,280,000 and working capital of $9,155,000$8,616,000 at December 31, 2020.2021. We have primarily financed operations through private and public placement of equity securities and our line of credit facility.
The Company has a Revolving Credit Agreement with Boyalife Asset Holding II, Inc. As of June 30, 2021, the Company had drawn down the full $10,000,000 that is available under the Revolving Credit Agreement, which matures in March of 2022. Boyalife Asset Holding II, Inc. is a wholly-owned subsidiary of Boyalife Group Inc. (USA), which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors.
During 2020, the Company received a loan totalling net proceeds of $646,000 from the SBA under the Payment Protection Program of the CARES Act, in response to the COVID-19 pandemic described above. The CARES Act permits that a loan may be forgiven if certain criteria are met. In March 2021, the SBA approved the Company’s application to forgive the entire amount of the debt. In the six months ended June 30, 2021, the Company recognized a gain of the forgiveness of debt for $652,000 representing the principal balance and accrued interest related to the loan at the time of forgiveness.
The Company has incurred recurringhistorical losses from operations and expects to continue to incur operating losses and as of June 30, 2021 had an accumulated deficit of $260,235,000. These conditions raise substantial doubt aboutin the Company’s ability to continue as a going concern within one year from the filing of this report.near future. The Company may requireneed to raise additional capital to grow theits business, to fund other operating expenses and to make interest payments. The Company’s ability to fund its cashliquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through bankdebt borrowings, or public or private sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to us,the Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report.
We manage the concentration of credit risk with our customers and distributors through a variety of methods including, pre-shipment deposits, credit reference checks and credit limits. Although management believes that our customers and distributors are sound and creditworthy, a severe adverse impact on their business operations could have a corresponding material effect on their ability to pay timely and therefore on our net revenues, cash flows and financial condition.
Non-GAAP Measures
In addition to the results reported in accordance with US GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. The Company calculates adjusted EBITDA as income or (loss) from operations less depreciation, amortization, stock compensation, equity method investments and impairment of intangible assets. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable GAAP measure are provided below.
Three months ended June 30, 2021 and 2020, respectively:
| | | Three Months Ended June 30, | |
| | | 2021 | | | 2020 | |
Net loss | | $ | (4,672,000 | ) | | $ | (6,510,000 | ) |
| | | | | | | | | |
Deduct: | | | | | | | | |
Interest expense | | | (1,524,000 | ) | | | (1,314,000 | ) |
Other expense | | | (10,000 | ) | | | (8,000 | ) |
Loss from operations | | $ | (3,138,000 | ) | | $ | (5,188,000 | ) |
| | | | | | | | | |
Add: | | | | | | | | |
Depreciation and amortization | | | 154,000 | | | | 193,000 | |
Stock-based compensation expense | | | 2,099,000 | | | | 314,000 | |
Adjusted EBITDA | | $ | (885,000 | ) | | $ | (4,681,000 | ) |
Adjusted EBITDA for the three months ended June 30, 2021 was a loss of $885,000, compared to a loss of $4,681,000 for the three months ended June 30, 2020, an increase of $3,796,000. The adjusted EBITDA improvement was primarily due to lower inventory reserve expense of approximately $3,600,000 related to COVID-19 testing kits which was incurred in the three months ended June 30, 2020. Additionally, the three months ended June 30, 2020 had approximately $100,000 in fixed asset impairment expense, with no similar charges occurring in the three months ended June 30, 2021.
Six months ended June 30, 2021 and 2020, respectively:
| | | Six Months Ended June 30, | |
| | | 2021 | | | 2020 | |
Net Loss | | $ | (7,203,000 | ) | | $ | (11,253,000 | ) |
| | | | | | | | | |
Deduct: | | | | | | | | |
Interest expense | | | (3,043,000 | ) | | | (4,845,000 | ) |
Other income (expense) | | | (11,000 | ) | | | (11,000 | ) |
Gain on extinguishment of debt | | | 652,000 | | | | -- | |
Loss from operations | | $ | (4,801,000 | ) | | $ | (6,397,000 | ) |
| | | | | | | | | |
Add: | | | | | | | | |
Depreciation and amortization | | | 320,000 | | | | 392,000 | |
Stock-based compensation expense | | | 2,357,000 | | | | 381,000 | |
Adjusted EBITDA | | $ | (2,124,000 | ) | | $ | (5,624,000 | ) |
The adjusted EBITDA loss was $2,124,000 for the six months ended June 30, 2021 compared to a loss of $5,624,000 for the six months ended June 30, 2020, an increase of $3,500,000. The adjusted EBITDA improvement was primarily due to lower inventory reserve expense of approximately $3,500,000 primarily related to COVID-19 testing kits which was incurred in the six months ended June 30, 2020. Additionally, the six months ended June 30, 2020 also had $225,000 more in research and development salaries and benefits, approximately $100,000 in fixed asset impairment expense and approximately $50,000 in annual meeting expenses. Offsetting the increased expenses incurred in the six months ended June 30, 2020 was a decrease in gross profit provided by the AXP product line. The six months ended June 30, 2021 had 900 fewer cases of AXP disposables sold as compared to the same period in 2020, resulting in approximately $700,000 less in gross profit.
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
ThermoGenesis Holdings is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information under this item.
ITEM 4. Controls and Procedures
The Company carried out an evaluation, under the supervision, and with the participation of management, including both the Company’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) or 15d-15(e)) as of June 30, 2021.March 31, 2022. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have both concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2021.March 31, 2022.
There were no changes in the Company’s internal controls over financial reporting that occurred during the three months ended June 30, 2021March 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.Legal Proceedings
In the normal course of operations, we may have disagreements or disputes with distributors, vendors employees or other parties.employees. Such potential disputes are seen by management as a normal part of business and while the outcome of such disagreements and disputes cannot be predicted with certainty, except as described below, we do not believe that any pending legal proceedings are material. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
The material set forth in Note 8, “Commitments and Contingencies,” in “Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements” is incorporated herein by reference.
ITEM 1A. RISK FACTORS.Risk Factors
There have been no material changes to the risk factors relating to the Company set forth in f, “Item IA. Risk Factors” of its Annual Report on Form 10-K for the year ended December 31, 2020.2021.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.Unregistered Sales of Equity Securities and Use of Proceeds
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.Defaults Upon Senior Securities
None.
ITEM 4. MINE SAFETY DISCLOSURE.Mine Safety Disclosure
Not applicable.
ITEM 5. OTHER INFORMATION.Other Information
None.
ITEM 6.EXHIBITS.
An index of exhibits is found on page 26 of this report.
ItemITEM 6. Exhibits.Exhibits
Exhibit No. | Description |
1.1 | At the Market Offering Agreement, dated December 13, 2019 by and between ThermoGenesis Holding, Inc. and H.C. Wainwright & Co., LLC incorporated herein by reference to Exhibit 1.2 to the Registration Statement on Form S-3 (Registration No. 333-235509) filed on December 13, 2019. |
1.2 | Amendment No. 1 to At the Market Offering Agreement, dated May 19, 2020, between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC, incorporated herein by reference to Exhibit 1.1 to the Form 8-K filed on May 20, 2020. |
1.3 | Amendment No. 2 to At the Market Offering Agreement, dated February 3, 2022, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC, incorporated herein by reference to Exhibit 1.3 to the Form 8-K filed on February 3, 2022. |
| 3.1 | Amended and Restated Certificate of Incorporation of ThermoGenesis Holdings, Inc. dated as of June 5, 2020, incorporated by reference to Exhibit 3.1 to Form 8-K filed June 6, 2020. |
| 3.2 | Amended and Restated Bylaws of ThermoGenesis Holdings, Inc., incorporated by reference to Exhibit 3.2 to Form 8-K filed with the SEC on October 30, 2019. |
| 3.3 | First Amendment to the Amended and Restated Bylaws of ThermoGenesis Holdings, Inc., incorporated by reference to Exhibit 3.1 to Form 8-K filed December 17, 2021. |
| 4.1 | Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 to Form 8-K filed with the SEC on March 28, 2018. |
| 4.2 | Form of Common Warrant, incorporated by reference to Exhibit 10.37 of amended Registration Statement on Form S-1 filed with the SEC on May 14, 2018. |
| 4.3 | Investors’ Rights Agreement, dated January 1, 2019, among CARTXpress Bio, Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P., incorporated by referenced to Exhibit 10.3 to Form 8-K filed with the SEC on January 4, 2019. |
| 4.4 | Form of Convertible Promissory Note, dated as of July 23, 2019, between ThermoGenesis Holdings, Inc. and Orbrex USA Co., incorporated by reference to Exhibit 4.1 to Form 8-K filed with the SEC on July 29, 2019. |
| 4.5 | Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended, incorporated by reference to Exhibit 4.8 to Form 10-K filed with the SEC on March 24, 2020. |
10.1 | Fourth Amendment to the Company’s Amended 2016 Equity Incentive Plan, Effective June 4, 2020, incorporated by reference to exhibit 10.1 to Form 8-K filed January 14, 2022. |
10.2 | Amended 2016 Equity Incentive Plan, incorporated by reference to exhibit 10.2 to Form 8-K filed January 14, 2022. |
10.3 | Amendment No.1 to Second Amended and Restated Convertible Promissory Note, Dated March 4, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Asset Holding II, Inc. |
10.4 | Amendment No. 2 to First Amended and Restated Revolving Credit Agreement, dated March 4, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Asset Holding II, Inc. |
10.5 | License and Technology Access Agreement, dated March 24, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Genomics Tianjin Ltd. |
10.6 | Lease Agreement, dated March 24, 2022, between ThermoGenesis Holdings, Inc. and Z3 Investment LLC. |
31.1 | Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002 |
101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
101.SCH | Inline XBRL Taxonomy Extension Schema Document |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as(embedded within the Inline XBRL and contained in Exhibit 101). |
ThermoGenesis Holdings, Inc.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | ThermoGenesis Holdings, Inc. (Registrant) |
| | | |
| | |
Dated: August 12, 2021May 19, 2022 | | /s/ Xiaochun (Chris) Xu, Ph.D. |
| | | Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer) |
| | |
| | |
Dated: August 12, 2021May 19, 2022 | | /s/ Jeffery Cauble |
| | | Jeffery Cauble Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |